KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Leases (2019 - 2025)

Pfizer has reported Leases over the past 7 years, most recently at $2.2 billion for Q4 2025.

  • Quarterly Leases fell 3.32% to $2.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 billion through Dec 2025, down 3.32% year-over-year, with the annual reading at $2.2 billion for FY2025, 3.32% down from the prior year.
  • Leases was $2.2 billion for Q4 2025 at Pfizer, down from $2.3 billion in the prior quarter.
  • Over five years, Leases peaked at $3.0 billion in Q4 2022 and troughed at $2.2 billion in Q4 2025.
  • The 5-year median for Leases is $2.8 billion (2021), against an average of $2.7 billion.
  • Year-over-year, Leases surged 104.83% in 2021 and then decreased 21.72% in 2024.
  • A 5-year view of Leases shows it stood at $2.8 billion in 2021, then rose by 5.74% to $3.0 billion in 2022, then fell by 2.6% to $2.9 billion in 2023, then decreased by 21.72% to $2.3 billion in 2024, then decreased by 3.32% to $2.2 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Leases are $2.2 billion (Q4 2025), $2.3 billion (Q4 2024), and $2.9 billion (Q4 2023).